A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD) | NeoGenomics Laboratories

Publication date

Fri, 06/02/2023 - 12:00

Category

Year

Subtitle

ASCO 2023

File

ASCO_2023_A_phase_II_single-arm_open-label_trial_of_T-DM1_ado-trastuzumab%20emtansine_And_Neratinib_for_HER2%2B_Breast_Cancer_with_Molecular_Residual_Disease_KAN-HER2_MRD.pdf (6.03 MB)

Division